Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late, which are much lower than the gains experienced till mid-February. The San Francisco, ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Jefferies analyst Glen Santangelo raised the firm’s price target on Hims & Hers to $25 from $21 and keeps a Hold rating on the shares. A ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.